Market Overview

Citi: Solid Biosciences Rally Unsupported By Fundamentals

Share:
Citi: Solid Biosciences Rally Unsupported By Fundamentals

Following the near 100% rally in shares of Solid Biosciences Inc (NASDAQ: SLDB) in August, one Citigroup analyst said the stock price is diverging from worsening fundamentals.

The Analyst

Joel Beatty downgraded Solid Biosciences from Neutral to Sell and maintained a $6 price target.

The Thesis

Solid Bioscience's gene therapy candidate SGT-001 for treating Duchenne muscular dystrophy is unlikely to be approved in the U.S. in its current form because of dystrophin expression data that is unlikely to be competitive, even with the recent increased dosing, Beatty said in a Wednesday note. (See his track record here.)

Even if the increased dosing brings about the desired result, the analyst said he sees additional challenges pressuring the stock. The company could lag in manufacturing given its low cash levels, which could impact further enrollment in clinical trials and commercialization, he said. 

The anemic cash balance also makes the company a less attractive acquisition target, Beatty said. 

With Solid Biosciences trailing behind Sarepta Therapeutics Inc (NASDAQ: SRPT) and Pfizer Inc. (NYSE: PFE) in the race to the market, the former could be forced to pitch its therapy to difficult-to-treat, mostly older, heavier patients, the analyst said. 

"Using SLDB and PFE's percent dystrophin positive fibers data as a surrogate for transduction efficiency, we model that SLDB could achieve a transduction efficiency in the 40-60% range at their current dosing of 2E14 vg/kg, which, even at the high end of the range, is still considerably inferior to SRPT's ~81%." 

The Price Action

Solid Bioscience shares were tumbling 10.34% to $8.15 at the time of publication Thursday. 

Related Links:

Biotech Stock On The Radar: MyoKardia Bets On Precision Medicine For Heart Health

Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates

Latest Ratings for SLDB

DateFirmActionFromTo
Nov 2019MaintainsBuy
Oct 2019Initiates Coverage OnOutperform
Aug 2019DowngradesNeutralSell

View More Analyst Ratings for SLDB
View the Latest Analyst Ratings

Posted-In: Citigroup Joel BeattyAnalyst Color Biotech Downgrades Price Target Analyst Ratings Best of Benzinga

 

Related Articles (PFE + SLDB)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
THCBarclaysMaintains33.0
DVABarclaysMaintains79.0
ARABarclaysMaintains9.0
VRTXCantor FitzgeraldMaintains229.0
HCMCLSAInitiates Coverage On
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Mike Khouw Sees Unusual Options Activity In XRT

7 Tech Innovations In Sports That Changed The Game